Clinical Trial Update: Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of niclosamide and enzalutamide in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Niclosamide (niclosamide)
• Xtandi (enzalutamide)

Snippet

Sponsor: University of Washington | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Status: COMPLETED